Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab in relapsing-remitting multiple sclerosis
2017-000426-35Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in multiple sclerosis (MS) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Annualized relapse rate at 48 weeks. Started Mar 2018; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-000426-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000426-35.